The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
48-week open label randomized phase IV investigator initiated intervention study. The purpose
of this study is to evaluate whether HIV-1 suppression can be maintained by DTG monotherapy
in HIV-1 infected, virologically suppressed patients on cART.
104 adults fulfilling the in and exclusion criteria and on stable cART will be randomized
over 2 investigational arms.
The first arm will contain the direct switch population. This population will switch directly
from stable cART to Dolutegravir mono-therapy on baseline visit.
The second arm will contain the delayed-switch population. This group will switch from stable
cART to Dolutegravir monotherapy 24 weeks after baseline visit.
The main goal is to investigate if Dolutegravir mono-therapy could be non-inferior to cART in
virological suppressed HIV-1 infected adults.
If a interim analysis (performed when 40 patients on dolutegravir monotherapy have passed
week 12) shows that it is safe to continue the study, an additional 30 patients will be
included on top of the 104 patients needed for the primary endpoint analysis. In contrast to
the primary endpoint population, these additional 30 patients will have a CD4 nadir <200 but
a CD4 >350 at the time of the screening visit. Besides that, these 30 patients will have to
fulfill all other in and exclusion criteria of the primary endpoint population (specifically
a viral load never >100.000). These 30 patients are part of a pilot study looking at the
possibility to broaden the eligible population in a future larger randomized clinical trial.